Ascendis Pharma A/S (ASND)
136.30
4.73 (3.60%)
At close: Jan 15, 2025, 10:10 AM
Company Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs.
The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S
| Country | DK |
| IPO Date | Jan 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 879 |
| CEO | Jan Moller Mikkelsen |
Contact Details
Address: Tuborg Boulevard 12 Hellerup, DK | |
| Website | https://ascendispharma.com |
Stock Details
| Ticker Symbol | ASND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001612042 |
| CUSIP Number | 04351P101 |
| ISIN Number | US04351P1012 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director |
| Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer & Member of the Executive Board |
| Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research & Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President & Head of Clinical Development for Oncology |
| Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board |
| Mads Bodenhoff | Senior Vice President of Finance & Principal Accounting Officer |
| Timothy J. Lee | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 6-K | Filing |
| Jan 13, 2025 | 6-K | Filing |
| Dec 30, 2024 | 6-K | Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 12, 2024 | 6-K | Filing |
| Dec 11, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 6-K | Filing |
| Nov 14, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |